Guru Sonpavde, GU Oncology and Phase I Clinical Trials Director, Chair of Bladder Cancer Research at AdventHealth Central Florida, Professor of Medicine at the University of Central Florida, and at Loma Linda University Health, shared a post on LinkedIn about a paper he co-authored with colleagues published in JITC, BMJ Journals:
“Precision immunotherapy across cancers – pleased to write a commentary in Journal for ImmunoTherapy of Cancer from Adventhealth Cancer Institute Central Florida with Jason Brown – Incorporation of readily available clinical factors (eg, sites of metastasis, histology), host genetics, orthogonal molecular platforms (genomics, transcriptomics, microbiome, computational pathology, spatial transcriptomics, epigenetics, proteomics, radiomics) and investigating biomarkers to predict both sensitive and primary refractory disease in addition to severe toxicities is necessary to facilitate precision oncology.”
Title: Toward a better pan-tumor predictive signature for unleashing precision immuno-oncology
Authors: Jason R. Brown, Guru Sonpavde
You can read the full article in Journal for ImmunoTherapy of Cancer.
More posts featuring Guru Sonpavde.